WXIBF (WuXi Biologics (Cayman)) Beginning Cash Position: $1,198 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXIBF WuXi Biologics (Cayman) Inc WXIBF
100 GF Score
Price $4.60
GF Value $5.17
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Beginning Cash Position?

WuXi Biologics (Cayman) WXIBF 100 Beginning Cash Position is $1,198 Mil as of Dec. 2025. GuruFocus rates WXIBF with a GF Score™ of 100/100 and a GF Value™ of $5.17 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WuXi Biologics (Cayman)'s Beginning Cash Position for the quarter that ended in Dec. 2025 was $1,198 Mil.

WuXi Biologics (Cayman)'s quarterly Beginning Cash Position declined from Dec. 2024 ($1,257 Mil) to Jun. 2025 ($1,153 Mil) but then increased from Jun. 2025 ($1,153 Mil) to Dec. 2025 ($1,198 Mil).

WuXi Biologics (Cayman)'s annual Beginning Cash Position increased from Dec. 2023 ($896 Mil) to Dec. 2024 ($1,328 Mil) but then declined from Dec. 2024 ($1,328 Mil) to Dec. 2025 ($1,175 Mil).

WuXi Biologics (Cayman) Beginning Cash Position Related Terms

WuXi Biologics (Cayman) Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Beginning Cash Position Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,114.05 1,291.40 895.66 1,328.15 1,175.49

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,030.10 1,332.91 1,257.23 1,153.03 1,198.19
WXIBF
100GF Score
WuXi Biologics (Cayman) Inc WXIBF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $1,198 Mil mean?
WuXi Biologics (Cayman) (WXIBF) has a Beginning Cash Position of $1,198 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Beginning Cash Position too high?
WuXi Biologics (Cayman)'s current Beginning Cash Position is $1,198 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Beginning Cash Position compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Beginning Cash Position of $1,198 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Beginning Cash Position is $1,198 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.17, compared to a current price of $4.60 — trading 11% below its estimated fair value. The current Beginning Cash Position is $1,198 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Beginning Cash Position is $1,198 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.60 is trading 11% below its estimated GF Value™ of $5.17. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Beginning Cash Position: $1,198 Mil
  • GF Value™: $5.17 vs. price of $4.60 (11% below fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
100GF Score

Get the complete analysis for WXIBF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.60
Price
$5.17
GF Value